CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
0.4556
-0.0875 (-16.11%)
At close: Apr 4, 2025, 4:00 PM
0.4604
+0.0048 (1.05%)
After-hours: Apr 4, 2025, 7:49 PM EDT

CytomX Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
31.87-0.57-99.32-115.87-64.82
Upgrade
Depreciation & Amortization
1.772.182.442.712.57
Upgrade
Asset Writedown & Restructuring Costs
0.11-0.25--
Upgrade
Loss (Gain) From Sale of Investments
-5.31-7.42-0.050.27-0.24
Upgrade
Stock-Based Compensation
7.678.5613.1313.1714.79
Upgrade
Other Operating Activities
4.083.733.413.132.89
Upgrade
Change in Accounts Receivable
0.3332.55-35.20.01-0.79
Upgrade
Change in Accounts Payable
-0.3-1.430.07-0.14-0.86
Upgrade
Change in Unearned Revenue
-118.25-89.0116.57-33.9562.83
Upgrade
Change in Other Net Operating Assets
-8.2-4.63-12.0911.64-11.12
Upgrade
Operating Cash Flow
-86.23-56.04-110.79-119.035.26
Upgrade
Capital Expenditures
-0.31-0.84-1.74-1.61-2.31
Upgrade
Investment in Securities
100.01-149.8310024.1-16.41
Upgrade
Investing Cash Flow
99.7-150.6798.2622.49-18.72
Upgrade
Issuance of Common Stock
7.520.560.65110.2116.89
Upgrade
Other Financing Activities
-29.67---
Upgrade
Financing Cash Flow
7.5230.230.65110.2116.89
Upgrade
Net Cash Flow
20.99-176.48-11.8813.673.43
Upgrade
Free Cash Flow
-86.54-56.88-112.53-120.642.95
Upgrade
Free Cash Flow Margin
-62.66%-56.19%-211.67%-323.33%4.31%
Upgrade
Free Cash Flow Per Share
-1.02-0.77-1.71-1.880.06
Upgrade
Levered Free Cash Flow
-44.243.66-8.92-46.11-53.86
Upgrade
Unlevered Free Cash Flow
-44.243.66-8.92-46.11-53.86
Upgrade
Change in Net Working Capital
68.95-37.82-35.9-12.1618.57
Upgrade
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q